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Summary
Background: This study investigated the effects of a nutri-
tionally relevant intake of eicosapentaenoic (EPA) and
docosahexaenoic (DHA) fatty acids derived from oily fish or
a fish oil supplement on selected cardiovascular risk factors
in average middle-aged individuals.
Methods: Thirty-three participants were randomized to
receive salmon (oily fish) providing 274 mg EPA + 671 mg
DHA/day or a commercial fish oil supplement providing
396 mg EPA + 250 mg DHA/day in a cross-over trial over
an 8-week period separated by a 6-month washout period.
Blood samples were collected before and after each inter-
vention and lipids, inflammatory and oxidative stress
parameters were determined.
Results: Plasma levels of EPA, DHA and total n-3 fatty acids
significantly increased after both interventions. A decreas-
ing trend in triglycerides was more pronounced with
salmon than with the fish oil supplement, but the changes
noticed were not significant. Although there were no rele-
vant changes in inflammatory marker concentrations at the
end of both interventions, significant negative correlations
were noticed between total plasma n-3 fatty acids and sol-
uble intercellular adhesion molecule and C-reactive protein
Kratak sadr`aj
Uvod: U ovoj studiji pra}eni su efekti preporuka za unos
eikozapentaenske (EPA) i dokozoheksaenske kiseline
(DHA), iz dva razli~ita izvora, lososa i suplementa sa ribljim
uljem, na odabrane faktore kardiovaskularnog rizika u
prose~noj populaciji srednjih godina.
Metode: Trideset i tri ispitanika su po slu~ajnom izboru
konzumirali losos koji je obezbe|ivao 274 mg EPA + 671
mg DHA/dan ili komercijalni suplement ribljeg ulja koji je
obezbe|ivao dnevno 396 mg EPA + 250 mg DHA tokom
8 nedelja. Nakon perioda od 6 meseci ispitanicima su
zamenjene intervencije (ukr{tena studija). Uzorci krvi su
sakupljani pre i posle svake intervencije, a zatim su
odre|ivani lipidni, inflamatorni parametri kao i markeri
oksidativnog stresa.
Rezultati: Koncentracije EPA, DHA i ukupnih n-3 masnih
kiselina u plazmi su zna~ajno pove}ane posle obe inter -
vencije. Nije bilo statisti~ki zna~ajnih promena u lipidnim
parametrima, iako je zabele`eno ve}e smanjenje nivoa
trigli cerida posle intervencije lososom u pore|enju sa
suplementom. Nisu uo~ene zna~ajne promene u koncen-
traciji inflamatornih markera, ali je utvr|ena zna~ajna
nega tivna korelacija izme|u ukupnih n-3 masnih kiselina
List of abbreviations: AHA, American Heart Association;
ANOVA, analysis of variance; BMI, body mass index; CRP, C-
reactive protein; DHA, docosahexaenoic acid; EPA, eicos-
apentaenoic acid; FAME, fatty acid methyl ester; LC PUFA,
long-chain polyunsaturated fatty acid; MDA, malondialde-
hyde; O2
–, superoxide anion; sICAM-1, soluble intercellular
adhesion molecule; sVCAM-1, soluble vascular cell adhesion
molecule; TAS, total antioxidant status; TG, triglyceride.
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Introduction
It is widely accepted that n-3 polyunsaturated
fatty acids (PUFA), especially long chain (LC) eicosa -
pentaenoic (EPA, 20:5 n-3) and docosahexaenoic
acid (DHA, 22:6 n-3), have several physiological roles
in the human organism that can explain their positive
impact on cardiovascular events. LC n-3 PUFA are
present mainly in oily fish and commercially available
supplements (as concentrated pharmaceutical prepa-
rations), and dietary guidelines recommend use of
these fatty acids for the purpose of primary and sec-
ondary cardiovascular prevention. There is docu-
mented evidence that cardioprotective effects of n-3
PUFA may be mediated by their anti inflammatory
properties, lipid-modulating effects, as well as
antithrombotic and vasodilatory effects (1, 2). In
numerous human studies, low dietary intake of n-3
fatty acids had no effect on inflammatory markers in
healthy individuals (3); however, in several studies the
concentration of soluble intercellular adhesion mole-
cule (sICAM-1), soluble vascular cell adhesion mole-
cule (sVCAM-1), and C-reactive protein (CRP) was
affected, which was dependent on the dose and dura-
tion of the study (4, 5). Although LC n-3 PUFA play a
role in the modification of lipid and lipoprotein
metabolism, it is obvious that these effects become
evident at higher daily doses of EPA and DHA (1).
The influence of diet on prooxidative and antioxida-
tive processes is still an intriguing area, due to lack of
proper indicators of increased oxidation in vivo. There
is no clear evidence whether dietary or supplemental
n-3 PUFA can reduce oxidative stress, although some
experimental data support the notion that a high
intake of PUFA may increase in vivo lipid peroxidation
(6). 
Despite sometimes conflicting results of individ-
ual clinical trials as well as meta-analyses of n-3 fatty
acids impact on cardiovascular outcomes, the current
evidence is sufficient to encourage an intake of
500–1000 mg of EPA+DHA daily in primary and
secondary prevention of cardiovascular disease,
either in the form of two fatty fish meals per week, or
in the form of fish oil supplements (7, 8). Regardless
the so-far collected information from fish and fish oil
supplement clinical trials, there is still a need for more
controlled studies in specific populations and with
specific clinical targets. So far, few studies have been
conducted on the effect of n-3 fatty acids in the
Serbian population, especially in average healthy mid-
dle-aged individuals which are characterized by one
or more cardiovascular risk factors and a low level of
fish consumption (9–11). These facts suggest this
population is in need of improvement of dietary
habits, either by increasing fish intake or by incorpo-
rating fish oil supplements in regular diet. 
The primary aim of this study was to investigate
the relationship between the recommended intake of
n-3 fatty acids from oily fish or fish oil supplements
and selected cardiovascular risk markers in healthy
Serbian adults that included blood lipid parameters,
circulating inflammatory markers and oxidative stress
parameters. The secondary aim was to explore the
differences between the effects of two generally-
accepted food-based dietary recommendations for
LC n-3 PUFA intake from two dietary sources. In
order to avoid variations between participants, we
implemented a randomized cross-over trial.
Materials and Methods
Subjects
Thirty-five volunteers without any known me di -
cal condition (17 female and 18 male), aged
between 44 and 64, body mass index (BMI) <30
kg/m2 and blood pressure <140/90 mmHg, were
enrolled into the intervention study. Exclusion criteria
were as follows: recent weight changes (± 3 kg); con-
sumption of fish oil, calcium or vitamin D supple-
ments in the last three months; use of any regular
medications known to affect plasma lipid levels or
nonsteroidal antiinflammatory drugs such as aspirin;
more than 10 cigarettes per day; an allergy or into l -
erance to fish. Further exclusion criteria were concen-
throughout the whole intervention period (p<0.05).
Among the oxidative stress parameters, intervention with
salmon showed a prooxidative effect through a superoxide
anion increase (p=0.025). A relevant positive correlation
was also found between its concentration and total plasma
n-3 fatty acids (p<0.05). Other oxidative stress markers
were not significantly influenced by the dietary interven-
tions applied.
Conclusions: Following two sets of recommendations for n-
3 fatty acids intake aimed at the general public had only a
moderate effect on the selected cardiovascular risk factors
in average healthy middle-aged subjects over a short-term
period.
Keywords: n-3 fatty acids, fish and fish oil supplements,
circulating inflammatory markers, oxidative stress, cardio-
vascular disease
plazme i rastvorljivog intracelularnog adhezionog molekula
i C-reaktivnog proteina tokom ukupnog trajanja studije
(p<0,05). Od parametara oksidativnog stresa, intervencija
lososom je imala umeren prooksidativni efekat usled pove -
}anja superoksidnog anjona (p=0,025). Izme|u ovog
para metra i ukupnih n-3 masnih kiselina na|ena je sta-
tisti~ki zna~ajna pozitivna korelacija. Ostali markeri oksida-
tivnog stresa nisu se zna~ajno menjali.
Zaklju~ak: Preporu~ene vrednosti za unos n-3 masnih kise -
lina pokazale su umeren efekat na parametre kardiovas -
kularnog rizika u prose~noj populaciji srednjih godina u
kratkom periodu trajanja studije.
Klju~ne re~i: n-3 masne kiseline, riba i suplementi
ribljeg ulja, cirkulatorni inflamatorni markeri, oksidativni
stres, kardiovaskularne bolesti
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trated on participants who habitually consumed more
than one fish meal per week and were drinking more
than three standard alcoholic drinks per day. The cri-
terion for dyslipidemic status was low-density lipo -
protein cholesterol (LDL-C) concentration above 3.36
mmol/L and/or triglyceride (TG) concentration more
than 1.69 mmol/L according to the National Cho -
lesterol Edu cation Program Guidelines (12). The
baseline data collected at the time of the first clinical
visit are shown in Table I.
The study was approved by the Clinical Re -
search Ethics Committee of the Faculty of Pharmacy,
University of Belgrade, Serbia. Informed consent was
obtained from all subjects before starting experimen-
tal procedures and the study followed the Helsinki
guidelines.
Intervention
Dietary intervention was designed as a random-
ized, cross-over trial. Participants were randomly
assigned at the beginning of the trial to one of the two
treatment orders. Participants were randomized to
either: Group 1: eight weeks of salmon consumption
followed by a six-month washout period followed by
eight weeks of fish oil supplementation; Group 2:
eight weeks of fish oil supplementation followed by a
six-month washout period followed by eight weeks of
salmon consumption. Participants were asked not to
consume any additional oily fish during the study peri-
od, but were otherwise encouraged to follow their nor-
mal dietary habits. During the salmon intervention,
participants received 150 g of cold smoked skinned fil-
let of Norwegian Atlantic farmed salmon two times
per week (by Squadra, d.o.o., Belgrade, Serbia). Fish
oil capsules used contained 1000 mg of fish oil/cap-
sule in the form of triglycerides (Pharmanova d.o.o.,
Belgrade, Serbia) and were typical of commercially
available dietary supplements given in the amount that
was most frequently recommended by the producers.
The whole trial included four clinical visits, one before
and one after each intervention period. The following
assays were performed at all four visits. To monitor
changes in energy intake, participants completed a 3-
day food diary at two baseline points during the inter-
vention. Dietary data were analyzed by using CRON-
O-Meter v0.9.6. software. The mean energy and
macronutrient daily intake measured at two baseline
points is presented in Table II together with daily n-3
PUFA consumption from salmon and fish oil.
Biochemical analyses
Lipid status parameters (total cholesterol (TC),
LDL-C, high-density lipoprotein cholesterol (HDL-C)
and TG) were measured in serum, using an ILAB 300
plus analyzer (Instrumentation Laboratory, Milan,
Italy), employing commercial kits. Atherogenic index
of plasma (AIP) was calculated as TG/HDL-C ratio.
Table I Characteristics of the study population at baseline*
Characteristics Whole group (n=35)
Gender (female/male) 17/18
Age (range, years) 55 (46–64)
Smokers, n (%) 9 (26%)
Body weight (kg) 79.5±14.0
BMI (kg/m2) 26.1±3.4
Overweight, n (%) 19 (54%)
Total cholesterol (mmol/L) 6.55±0.93
LDL cholesterol (mmol/L) 4.28±0.89
HDL cholesterol (mmol/L) 1.47±0.36
Triglycerides (mmol/L) 1.77±0.94
Dyslipidemic, n (%) 25 (71%)
Fasting Glucose (mmol/L) 5.1±0.57
Blood pressure (mm Hg)
Systolic 129.4±10
Diastolic 83.0±7.5
sICAM-1 (ng/mL) 246 (155–375)
sVCAM-1 (ng/mL) 508 (343–819)
CRP (mg/L) 1.2 (0.3–3.5)
O2
– (mmol/min/L) 110 (51–205)
MDA (mmol/L) 0.6 (0.2–1.1)
TAS (mmol/L) 0.7 (0.4–1.3)
*Values are presented as means ± SD or median (10th–90th
percentile).
BMI, body mass index; LDL, low-density lipoprotein; HDL,
high-density lipoprotein; sICAM-1, soluble intercellular adhe-
sion molecule; sVCAM-1, soluble vascular cell adhesion
mo l ecule; CRP, C-reactive protein; O2
–, superoxide anion;
MDA, malondialdehyde; TAS, total antioxidant status.
Table II Estimated daily energy intake and daily n-3 PUFA
intake from salmon and capsules.
Values for energy and macronutrients are presented as
means ± SD PUFA, polyunsaturated fatty acid; EPA, eicosa -










Total n-3 FAs 1206 704
Fatty acid analysis
Fish lipids for further fatty acid analysis were
extracted according to the method of Folch et al.
(13). Total lipids from plasma were extracted with
chloroform/methanol according to Folch, modified
by Kates (14). Fish, supplement and plasma lipids
were then transesterified with hydrochloric acid (HCl)
in methanol according to the method described by
Ichihara and Fukubayashi (15) and fatty acid methyl
esters were obtained (FAMEs). FAMEs were quanti-
fied using an Agilent Technologies 7890A Gas Chro -
matograph with a flame ionization detector (Agilent
Technologies, Santa Clara, CA, USA). Separation of
the FAMEs was performed on a 112–88A7, HP-88
capillary column (100 m × 0.25 mm × 0.2 mm) using
He as a carrier gas at a flow rate of 105 mL/min. The
samples were injected at a starting oven temperature
of 175 ˚C; injector temperature was 250 ˚C and
detector temperature was 280 ˚C.
The oven temperature was programmed to in -
crease from 175 ˚C to 220 ˚C at 5 ˚C/min. Fatty
acids were identified by their retention time with re f -
erence fatty acid standards (SupelcoTM FAME Mix,
USA).
Measurements of inflammatory markers
Serum ICAM-1, VCAM-1 and CRP levels were
determined using commercially available ELISA kits
(R&D Systems, Inc, USA).
Oxidative stress and antioxidative defense
parameters
The rate of superoxide anion (O2–) generation
was measured using the rate of nitro blue tetrazolium
(NBT) reduction (16). Plasma malondialdehyde (MDA)
concentrations were measured using the thiobarbi-
turic acid-reactive substances (TBARS) assay em -
ploying the molar absorption coefficient of 1.56 ×
105 M-1cm-1 and spectrophotometry at 535 nm as
previously described by Girotti et al. (17). Total antiox-
idant status (TAS) was determined using an automat-
ed method developed by Erel (18). The method is
based on the decoloration of 2.2'-azinobis-(3-ethyl-
benzothiazoline-6-sulfonic acid radical cation (ABTS)
by antioxidants present in serum. The color change
was measured using an ILab 300 Plus auto analyzer.
The reaction rate is calibrated with Trolox (water-solu-
ble analogue of vitamin E, 6-hydroxy-2, 5,7, 8-tetra -
methylchroman-2-carboxylic acid) and the TAS value
of the samples tested is expressed as mmol Trolox
equivalent/L. The intra-assay and inter-assay coeffi-
cients of variance were 4.3% and 8.8 %, respectively.
Statistical analysis
Data were evaluated by mixed model ANOVA.
All variables were tested for normal distribution of the
data. A large number of the test variables were not
normally distributed; therefore, non-parametric tests
were used in the statistical analysis, since data were
skewed (Mann–Whitney tests, Spearman correlation).
Normally distributed data were expressed as means
±SD or otherwise as medians and 10th and 90th per-
centiles or medians and interquartile range. To deter-
mine if there was a difference in outcome between fish
and fish oil supplements, the model fitted treatment
and period as fixed effects and participants and visits
as random effects, as described in our previous report
(19). Least square means and confidence intervals
were calculated for the differences between Salmon-
wk 0, Fish oil-wk 0, Salmon-wk 8 and Fish oil-wk 8, as
well as for the net difference between the interven-
tions, (Salmon wk 8 – Salmon wk 0) – (Fish oil wk 8 –
Fish oil wk 0). Exact values of p<0.05 were consid-
ered statistically significant. Analysis was carried out in
PASW (SPSS) version 18 (Chicago, IL, USA).
Results
Subjects
Only two participants withdrew from the study.
Thirty-three participants completed two phases of the
intervention with measurable outcomes at all visits.
The reason for withdrawal was poor compliance with-
in the study group. The baseline characteristics con-
sidering BMI, blood pressure, glucose level, energy
and macronutrient intake did not change during the
whole study period. The dietary analysis obtained
from the 3-day food diary showed that the mean
energy intake was slightly over the dietary reference
recommendation (20). All subjects were middle-aged
(mean age 55 years) and had one or two cardiovas-
cular risk factors at the beginning of the study (54%
overweight, 71% dyslipidemic). There were no signif-
icant differences in lipid parameters between groups
at baseline and after the washout phase. In spite of
the higher level of TG at baseline in salmon group
compared to fish oil group (2.01 mmol/L vs 1.76
mmol/L), this difference was not significant. During
the salmon intervention participants received 274 mg
EPA and 671 mg DHA daily, while intervention with
fish oil supplements provided daily amounts of 396
mg EPA and 250 mg DHA.
Plasma fatty acids and serum lipids
In Table III, changes in plasma fatty acid compo-
sition and serum lipids after 8 weeks of each interven-
tion are shown. Measurements of plasma fatty acid
concentration allow the evaluation of the net changes
associated with treatments. The initial plasma con-
centration of fatty acids was not different between
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groups at baseline and after the washout phase. Basal
level of plasma n-3 fatty acids, EPA and DHA was
4.7%, 0.52% and 3.07% respectively in salmon
group, and 4.8%, 0.54% and 3.50% in fish oil group.
The daily consumption of total n-3 fatty acids was
higher from salmon when compared with the level
consumed from fish oil supplements (1206 mg/day
vs 704 mg/day). Also, daily intake of DHA was high-
er from salmon, and EPA intake was higher from fish
oil supplements. After 8 weeks, there was a signifi-
cant increase in the level of EPA, DHA and total n-3
fatty acids in plasma of both groups. The percentage
values of EPA increased by 135% in salmon group
(p<0.0001) and 152% in fish oil group (p<0.0001),
whereas DHA increased by 145% in salmon
(p<0.0001) and 121% in fish oil group (p<0.010).
The increase in plasma total n-3 fatty acids observed
after 8 weeks of salmon consumption was greater
when compared with fish oil (45% vs 27%) (p<0.05).
After 8 weeks of dietary intervention with salmon and
fish oil, there were no statistically significant changes
in the analyzed lipid parameters in either group. TG
were the only lipid components that were noticeably
influenced, but only after salmon intervention.
Although a 15% decrease in TG was detected in
salmon group, resulting in 11.7% AIP decrease, both
changes were not statistically significant.
Inflammatory markers
Serum concentrations of the inflammatory
markers sICAM-1, sVCAM-1 and CRP are presented
in Figure 1. No significant changes were noticed in
either of the intervention groups, but some trends
could be detected. sICAM-1 levels slightly decreased
after both interventions, while serum levels of
sVCAM-1 and CRP were slightly higher after salmon,
and lower after fish oil intervention, compared with
the baseline values.
Oxidative stress biomarkers
The dynamic of summary changes in all the
analyzed oxidative stress parameters (O2
–, MDA, TAS)
during n-3 PUFA interventions is presented in Figure
2. We performed an analysis of oxidative stress
changes during the intervention period by analyzing
O2
– level and MDA status as oxidative stress markers.
Concentration of O2
– increased by 29% in salmon
group which was significant (p=0.025), and 9.5%
(p=0.218) in fish oil group after the intervention peri-
od. The increased levels of MDA noticed after both
fish and fish oil dietary intervention were not signifi-
cant (p=0.188 and p=0.869, respectively). Non-
enzymatic antioxidative protection, i.e. TAS concen-
tration was lowered slightly but not significantly after
both interventions compared to the baseline values
(p=0.307 for salmon and p=0.246 for fish oil).
Correlation coefficients between the plasma
level of n-3 fatty acids and serum lipids, inflammato-
ry and oxidative stress parameters were determined
(Table IV). The present study revealed a statistically
significant negative correlation between plasma n-3
fatty acids and sICAM-1 and CRP (p<0.05). On the
other hand, a significant positive correlation was
obtained between total n-3 fatty acids and O2
–
(p<0.05).
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Salmon Fish oil capsules
Baseline After Pa Baseline After Pb Pc
EPA (20:5n-3) 0.52±0.39 1.22±0.99 <0.0001 0.54±0.39 1.37±0.72 <0.0001 0.643
DHA (22:6n-3) 3.07±1.26 4.45±1.19 <0.0001 3.50±1.25 4.22±1.18 0.010 0.581
EPA+DHA 3.59±1.55 5.70±2.01 <0.0001 4.04±1.55 5.59±1.70 0.006 0.496
Total n-3 FAs 4.7±1.60 6.8±2.20 <0.0001 4.8±2.10 6.1±2.20 0.011 0.826
Total cholesterol 6.57±1.01 6.38±0.91 0.345 6.40±0.84 6.69±1.08 0.151 0.361
LDL (mmol/L) 4.29±0.88 4.24±0.85 0.754 4.23±0.80 4.46±0.86 0.234 0.870
HDL (mmol/L) 1.43±0.42 1.37±0.35 0.778 1.37±0.30 1.38±0.36 0.805 0.906
TG (mmol/L) 2.01±1.17 1.70±0.83 0.380 1.76±0.86 1.77±0.70 0.784 0.528
AIP 1.62±1.20 1.43±0.97 0.686 1.43±0.94 1.33±0.71 0.849 0.483
Table III Plasma n-3 FA composition (% of total fatty acids) and serum lipids at baseline and post-intervention according to study
group.
Values are expressed as mean ± SD.
aSignificance in mean values from baseline after salmon consumption.
bSignificance in mean values from baseline after fish oil capsule intervention.
cSignificance in mean values between groups at baseline.
EPA, eicosapentaenoic acid; DHA, docosahexaenoic acid; LDL, low-density lipoprotein; HDL, high-density
lipoprotein; TG, triglyceride; AIP, atherogenic index of plasma.
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Table IV Correlation coefficients between plasma level of n-3 FAs (n=140) and inflammatory markers and oxidative stress param-
eters before and after 8 weeks of each intervention with salmon and fish oil during the study period.
TC HDL LDL TG sVCAM-1 sICAM-1 CRP O2
– MDA TAS
EPA –0.119 0.057 –0.152 –0.145 0.063 –0.048 –0.143* 0.009 –0.066 0.177
DHA –0.109 0.065 –0.098 –0.118 –0.050 –0.077 –0.225* 0.139 –0.015 0.027
EPA+DHA –0.123 0.078 –0.118 –0.141 –0.024 –0.146 –0.231* 0.105 –0.025 0.095
Total n-3 FAs –0.121 0.053 –0.128 –0.104 –0.066 –0.186* –0.227* 0.176* –0.037 0.127
*Marked correlations are significant at p<0.05. TC, total cholesterol; HDL, high-density lipoprotein; LDL, low-density lipoprotein;
TG, triglyceride; sVCAM-1, soluble vascular cell adhesion molecule; sICAM-1, soluble intercellular adhesion molecule; CRP, C-
reactive protein; O2
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Figure 2 O2
–, MDA and TAS concentrations at baseline and
after 8 wks of dietary interventions with salmon and fish oil
capsules (points: S1–salmon before, S2–salmon after,
FO1–fish oil before, FO2–fish oil after). Values are expressed
as median and interquartile range. The difference in relation
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Figure 1 sICAM-1, sVCAM-1 and CRP concentrations at
baseline and after 8 wks of dietary intervention with salmon
and fish oil capsules (points: S1–salmon before, S2–salmon
after, FO1–fish oil before, FO2–fish oil after). Values are
expressed as median and interquartile range. The difference
in relation to baseline was significant at p<0.05 (*).
Discussion
This investigation analyzed the possibility of
modulating diverse cardiovascular risk factors with
nutritionally relevant doses of LC n-3 PUFA from two
different dietary sources in dyslipidemic middle-aged
subjects. Although some beneficial trends were
shown, the results of the present study suggested that
following two sets of recommendations for LC n-3
PUFA intake had only a moderate effect on the lipid
status, inflammatory or oxidative stress parameters.
The average middle-aged Serbian population is
characterized by one or more cardiovascular risk fac-
tors as was proven in several previous reports (9, 11).
According to the baseline values for serum lipids,
BMI, blood pressure and glucose levels, the chosen
group of participants represented a healthy middle-
aged Serbian population with moderately altered lipid
profile and increased BMI as risk factors. Subjects
received salmon (fatty fish) and used commercial fish
oil capsules during the cross-over intervention, with
no energy and macronutrient changes under the free
lifestyle conditions. Intervention was conducted tak-
ing into consideration two sets of dietary recommen-
dations for LC n-3 PUFA intake for preventive purpos-
es: two fish meals (preferably oily fish) per week for
primary prevention of cardiovascular disease (7, 8);
intake of a fish oil supplement in the quantity that is
the median of the recommended daily intake given
for these products by the producers (2 g/day). The
fish oil capsules used in the study were chosen to
ensure the best bioavailability of LC n-3 PUFA com-
parable to their bioavailability from fish (TG-binding
form) (21, 22), with the most common ratio of EPA
and DHA among n-3 supplements available on the
Serbian market (3/2). No matching for the total
amount of dietary n-3 PUFA, EPA, and DHA was
done in order to increase the ecological validity of the
study. Daily intake of EPA + DHA from salmon (945
mg) and from FOC (646 mg) was in accordance with
the general AHA recommendations. A cross-over was
used as a fairly unexplored study design in this kind of
investigation to compare two sets of dietary recom-
mendations for n-3 fatty acids intake coming from
fish and a fish oil supplement. 
Compliance to the study protocol was confirmed
by demonstration of changes in relevant fatty acids in
plasma phospholipids, because plasma FA take only
several hours or days to reflect the incorporation of
dietary n-3 fatty acids (23). Plasma n-3 fatty acid pro-
file was remarkably increased with both salmon and
fish oil capsules intervention. Increase in plasma EPA
and DHA levels was dose-dependent in both cases
and our results are in line with the results obtained in
other studies. Cao et al. (24) who supplemented their
participants with higher daily doses of EPA (1296 mg)
and DHA (864 mg) after 8 weeks of supplementation
noticed that the mean percent of EPA in plasma
increased by 245%, whereas DHA concentrations
increased by 73%. In the study of Harris (25), in
which EPA and DHA concentrations from fish and fish
oil capsules were matched, participants received 485
mg EPA+DHA during 16 weeks and this intervention
produced a 60–80% rise in plasma EPA+DHA. In the
studies mentioned the fatty acids from capsules were
in the form of ethyl esters, while in our trial the fatty
acids from both sources were in the form of triglyc-
erides (21, 22). 
Dyslipidemia is a traditional risk factor for athe ro -
sclerosis development and it is closely associated with
increased endothelial dysfunction. It has been report-
ed that LC n-3 PUFA can increase total cholesterol
concentration by 5% to 10% and decrease TG by 20%
to 50% (26, 27). Generally, the LC n-3 PUFA are used
because of their ability to decrease TG concentrations
(28). Participants in our study had slightly increased
values of TC, LDL-C and TG at baseline and the rec-
ommended doses of fish and fish oil supplements did
not result in significant changes in serum lipids,
although a positive trend in TG reduction was ob ser -
ved in the salmon group. This result is in accordance
with other authors, who reported no relevant changes
in cholesterol and TG levels in healthy subjects after a
6-week intervention with 927 mg EPA+DHA (29),
and after an 8-week intervention with 1200 mg
EPA+DHA (30). Differences that were noticed
between the salmon and supplement group in TG
reduction potential may be explained by the higher
level of TG at baseline in the salmon group compared
to the fish oil group (2.01 mmol/L vs 1.76 mmol/L)
and with the higher daily intake of total n-3 PUFA from
salmon compared to fish oil supplements (1206 mg/d
vs 704 mg/d). It seems that the effect on TG may be
expected at higher baseline values of TG, but also with
much higher doses of n-3 PUFA (1). EFSA health
claim for beneficial effects of EPA and DHA on TG
reduction specifies that 2 g daily intake is needed for
such a result, but this intake cannot be achieved by
following current general dietary recommendations.
Although the effect of salmon consumption on TG
level did not reach statistical significance, the 15%
decrease noticed may be of clinical importance.
Based on the fact that endothelial dysfunction is
the earliest manifestation of atherosclerosis along
with the involvement of inflammation and oxidative
stress at all stages of coronary atherosclerosis devel-
opment, inflammatory biomarkers such as sICAM-1,
sVCAM-1 and CRP are of particular interest (31–33).
There is some evidence that these parameters may be
regulated by fatty acids. In the current study, sICAM-
1, sVCAM-1 and CRP concentrations were not affect-
ed by the quantities of LC n-3 PUFA used. Lack of
direct association between fish or fish oil consumption
and sICAM-1 levels is in accordance with other
authors who reported no relevant differences in
sICAM-1 level after consumption of much higher
daily doses of EPA+DHA (34–36). Paulo et al. (37)
also showed that sICAM-1 concentration did not
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change, but sVCAM-1 concentration significantly
increased after eight weeks of intervention with oily
fish and fish oil diets providing 3003 mg/d of n-3
PUFA by salmon and 1418 mg of n-3 PUFA by fish
oil capsules. An increase in sVCAM-1 level was also
reported in healthy women taking 6.6 g/day of n-3
PUFA but not in the group taking 2 g/day during 12
weeks (34). Our findings support a possible dose-
dependent effect of n-3 PUFA on sVCAM-1 since low
levels of n-3 PUFA had no effect on this parameter in
our study. Both interventions in our study did not sig-
nificantly influence plasma CRP concentrations and
this is in accordance with the reports of Vega-Lopez et
al. (38) and Madsen et al. (39) who did not observe
any changes in the CRP serum levels, although some
studies have reported a decrease in CRP concentra-
tion with low doses of LC n-3 PUFA (40). It is gener-
ally accepted that the effects of LC n-3 PUFA on CRP
are highly variable (41).
An imbalance between the production of reac-
tive oxygen species and antioxidant defense leads to
oxidative stress and oxidative modification of LDL-
cholesterol (42). Beneficial effects of reactive oxygen
species are found only with physiologic low quantities
while their overproduction may cause cell damage.
Increased oxidative stress is involved in the develop-
ment of the atherosclerotic process and is one of the
risk factors for cardiovascular disease development. It
is well-known that PUFA are prone to peroxidation by
free radical products including reactive oxygen
species and that the length and number of double
bonds have great influence on the FA oxidative
capacity (43, 44). On the other hand, other studies
have shown that PUFA counteract the oxidative stress
(45), so that the role of PUFA in prooxidative/antiox-
idative balance is still controversial.
In the current study we measured O2
–, MDA and
TAS concentrations. The superoxide anion is consid-
ered to be a key player in oxidative stress. MDA is the
lipid peroxidation end product that is one of the most
reliable and widely used indices of oxidative stress.
TAS has been successfully used to show the body’s
ability to counteract oxidative stress since TAS repre-
sents many different plasma components with reduc-
ing power. The results from our study revealed elevat-
ed levels of both oxidative stress status parameters
(O2
–and MDA) and reduced protective TAS levels after
both interventions compared to baseline. Intervention
with salmon has shown a significant prooxidative
effect through O2
– increase during the study period
(p=0.025). The free radical disbalance noticed was
probably counteracted with other protective factors, so
we did not observe a  significant increase in MDA con-
centration (p=0.188). However, fish oil supplementa-
tion did not influence any of the two oxidative stress
markers measured in our current study in a significant
way (p=0.218 for O2
– and p=0.869 for MDA).
Intervention with salmon has shown stronger
prooxidative effects during the study period which
could be explained with the higher content of n-3
PUFA (6, 46). This effect seems to be in the physio-
logical range considering the values for the analyzed
parameters obtained previously in healthy Serbian
middle-aged subjects (47) and probably is part of the
protective mechanisms which enable antioxidative
gene expression activation as a reaction of the de -
fense system in order to lower lipid peroxidation (48).
In the present study, TAS levels slightly de creased
after both types of dietary intervention but this de -
crease was not statistically significant. In creased
antioxidant utilization is needed because of the higher
level of n-3 PUFA incorporation in the biological mem-
branes after interventions and this could be an expla-
nation for the decrease in measurable antioxidative
defense (49). 
Despite no relevant changes in inflammatory
markers after the nutritional salmon and fish oil diet,
we established significant negative correlations
between plasma n-3 PUFA and sICAM-1 or CRP
throughout the whole intervention period. This may
suggest that n-3 PUFA intake in the recommended
range may be beneficial with regard to the expression
of sICAM-1/CRP and contribute to decreased inflam-
mation in the vascular endothelium. A relevant posi-
tive correlation was found among plasma n-3 PUFA
and O2
–. We assume that these changes occurred nor-
mally as part of the physiological response.
There were some limitations to this study. The
small number of participants means that the study was
underpowered to detect all statistically significant dif-
ferences that might explain the trends observed for
some results. Also, the intervention period lasted 8
weeks, which may be too short to detect differences
between the two n-3 PUFA dietary sources. In conclu-
sion, following the two sets of dietary recommenda-
tions for LC n-3 PUFA aimed at the general public had
a similar and only moderate effect on lipid levels in
average healthy middle-aged Serbian subjects with low
fish consumption, primarily reducing the level of TG.
At the same time, the recommended doses did
not substantially change the levels of inflammation
markers and oxidative stress parameters. Consequ -
ently, a long-term follow-up could provide additional
insights into the effect of these interventions on se -
lected cardiovascular risk markers in this population.
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